Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier

To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.

Leqembi vials and boxes
• Source: Eisai

A US Food and Drug Administration advisory committee unanimously backed conversion from accelerated to regular approval for Eisai Co., Ltd. and Biogen, Inc.’s Alzheimer’s drug Leqembi (lecanemab-irmb), but panelists’ recommendations aimed at addressing safety concerns in some patient subgroups could result in tighter labeling for the anti-amyloid agent.

On the lone voting question, all six members of the Peripheral and Central Nervous System Drugs Advisory Committee on 9...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip